Download PDF
Semin Thromb Hemost 2002; 28(1): 79-88
DOI: 10.1055/s-2002-20566
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Improved Cancer Mortality with Low-Molecular-Weight Heparin Treatment: A Review of the Evidence

Richard H. Cosgrove1 , Leo R. Zacharski2 , Eric Racine3 , Judith C. Andersen4
  • 1Department of Pharmacy, Harper University Hospital, Detroit Medical Center, Detroit, Michigan
  • 2Department of Veteran's Affairs Medical Center, White River Junction, Vermont, and Department of Medicine, Dartmouth Medical School, Lebanon, New Hampshire
  • 3Clinical Pharmacy Services, Harper University Hospital, Detroit Medical Center and Wayne State University School of Pharmacy, Detroit, Michigan
  • 4Department of Medicine, Wayne State University, Harper University Hospital, Detroit, Michigan
Further Information

Publication History

Publication Date:
05 March 2002 (online)

    Permissions and Reprints

ABSTRACT

Work with low-molecular-weight heparins (LMWHs) continues to provide suggestions for survival advantages among patients with cancer diagnoses. Momentum is building in support of this theory through reports, the vast majority of which are derived from secondary analyses of clinical trials on the treatment of thromboembolism. The data retrieved from such studies that compare unfractionated heparin (UFH) with LMWH indicate that LMWH is equally beneficial if not more beneficial to cancer patients in terms of survival. In retrospective analysis, this improved life expectancy is not considered a result of reduced complications from thromboembolism. Thus, theories of antitumor effects of LMWH have developed, supported by evidence that most of the survival benefits are during long-term comparisons. Reports describing the effects of heparin in the setting of cancer have existed for over a half-century, although specific mechanisms for the marginal results seen thus far have yet to surface. Proposals for the most likely targets of the effective heparins include enzyme interaction, cellular growth modifications, and antiangiogenesis.

KEYWORD

Low-molecular-weight heparin - cancer - mortality

REFERENCES

  • 1 Prandoni P, Lensing A WA, Büller H R. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis.  Lancet . 1992;  339 441-445
    CrossrefPubMedGoogle Scholar
  • 2 The Columbus Investigators. Low-molecular weight heparin in the treatment of patients with venous thromboembolism.  N Engl J Med . 1997;  337 663-669
    CrossrefPubMedGoogle Scholar
  • 3 Levine M, Gent M, Hirsh J. A comparison of low-molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.  N Engl J Med . 1996;  334 677-687
    CrossrefPubMedGoogle Scholar
  • 4 Hull R D, Raskob G E, Pineo G F. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.  N Engl J Med . 1992;  326 975-982
    CrossrefPubMedGoogle Scholar
  • 5 Simonneau G, Charbonnier B, Decousus H. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.  Arch Intern Med . 1993;  153 1541-1546
    CrossrefPubMedGoogle Scholar
  • 6 The Tasman Study Group, Koopman M MW, Prandoni P, Piovella F. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home.  N Engl J Med . 1996;  334 682-687
    CrossrefPubMedGoogle Scholar
  • 7 Hull R D, Raskob G E, Brant R F. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism.  Arch Intern Med . 2000;  160 229-236
    CrossrefPubMedGoogle Scholar
  • 8 Leizorovicz A, Simonneau G, Decousus H, Boissel J P. Comparison of efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the initial treatment of deep venous thrombosis: a meta-analysis.  BMJ . 1994;  309 299-309
    PubMedGoogle Scholar
  • 9 Lensing A WA, Prins M H, Davidson B L, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis.  Arch Intern Med . 1995;  155 601-607
    CrossrefPubMedGoogle Scholar
  • 10 Hirsh J, Siragusa S, Cosmi B, Ginsberg J S. Low-molecular-weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism.  Thromb Haemost . 1995;  74 360-363
    PubMedGoogle Scholar
  • 11 Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg J. Low-molecular-weight heparin and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis.  Am J Med . 1996;  100 269-277
    CrossrefPubMedGoogle Scholar
  • 12 Gould M K, Dembitzer A D, Doyle R L, Hastie T J, Garber A M. Low-molecular-weight heparins compared with unfractionated heparin for the treatment of acute deep venous thrombosis, a meta-analysis of randomized controlled trials.  Ann Intern Med . 1999;  130 800-809
    CrossrefPubMedGoogle Scholar
  • 13 Ornstein D L, Zacharski L R. The use of heparin for treating human malignancy.  Haemostasis . 1999;  29(Suppl 1) 48-60
    CrossrefPubMedGoogle Scholar
  • 14 Dolovich L R, Ginsberg J S, Douketis J D, Holbrook A M, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism, examining some unanswered questions regarding location of treatment, product type, and dosing frequency.  Arch Intern Med . 2000;  160 181-188
    CrossrefPubMedGoogle Scholar
  • 15 Valentine K A, Hull R D, Pineo G F. Low-molecular-weight heparin and mortality.  Semin Thromb Hemost . 1997;  23 173-178
    PubMedGoogle Scholar
  • 16 von Tempelhoff G-F, Harenberg J, Niemann F. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial.  Int J Oncol . 2000;  16 815-824
    PubMedGoogle Scholar
  • 17 Hettiarachchi R JK, Smorenburg S M, Ginsberg J. Do heparins do more than just treat thrombosis?.  <~>The influence of heparins on cancer spread. Thromb Haemost . 1999;  82 947-952
    PubMedGoogle Scholar
  • 18 Wille Jørgensen P, Larsen I, Jørgensen L N, Lebeck M. Long term survival after operation for malignancies with and without long term prophylaxis with low-molecular-weight heparin (LMWH).  Thromb Haemost . 1995;  73 980-980 Abst
    PubMedGoogle Scholar
  • 19 Pineo G, Hull R, Raskob G, Brant R, Green D. Decreased mortality in cancer patients treated for proximal deep vein thrombosis with low-molecular-weight heparin as compared with unfractionated heparin.  Thromb Haemost . 1997;  Suppl 384-384 Abst
    PubMedGoogle Scholar
  • 20 von Tempelhoff F G, Dietrich M, Neimann F. Blood coagulation and thrombosis in patients with ovarian malignancy.  Thromb Haemost . 1997;  77 456-461
    PubMedGoogle Scholar
  • 21 Goerner A. The influence of anticlotting agents on transplantation and growth of tumor tissue.  J Lab Clin Med . 1930;  16 369-372
    PubMedGoogle Scholar
  • 22 Albert-Weil J, Nehorais J. Apropos de deux cas de néoplasies non-justiciable des thérapeutiques classiques, traitées par des injections intraveineuses d'héparine et des injections intramusculaires d'un extract de sangsue.  Rev Pathol Gen Comparee . 1954;  54 1014-1020
    PubMedGoogle Scholar
  • 23 Lebeau B, Chastang C, Brechot J-M. Subcutaneous heparin treatment increases survival in small cell lung cancer.  Cancer . 1994;  74 38-45
    CrossrefPubMedGoogle Scholar
  • 24 Kakkar A, Hedges A, Williamson R, Kakkar V. Perioperative heparin treatment inhibits late death from metastatic cancer.  Int J Oncol . 1995;  6 885-888
    PubMedGoogle Scholar
  • 25 Zacharski L R, Ornstein D L. Heparin and cancer.  Thromb Haemost . 1998;  80 10-23
    PubMedGoogle Scholar
  • 26 Ying Q L, Kemme M, Saunders D, Simon S R. Glycosaminoglycans regulate elastase inhibition by oxidized secretory leukoprotease inhibitor.  Am J Physiol . 1997;  272 1533-1541
    PubMedGoogle Scholar
  • 27 Ermolieff J, Boudier C, Laine A, Meyer B, Bierth J G. Heparin protects cathepsin G against inhibition by protein protease inhibitors.  J Biol Chem . 1994;  269 29502-29508
    PubMedGoogle Scholar
  • 28 Hermans J M, Monard D, Jones R, Stone S R. Inhibition of acrosin by serpins. A suicide substrate mechanism.  Biochemistry . 1995;  34 3678-3685
    CrossrefPubMedGoogle Scholar
  • 29 Hermans J M, Jones R, Stone S R. Rapid inhibition of the sperm protease acrosin by protein C inhibitor.  Biochemistry . 1994;  33 5440-5444
    CrossrefPubMedGoogle Scholar
  • 30 Adachi T, Marklaund S L. Interactions between human extracellular superoxide dismutase C and sulfated polysaccharides.  J Biol Chem . 1989;  264 8537-8541
    PubMedGoogle Scholar
  • 31 Kopitz J, Mukl C, Ehemann V, Lehmann C, Canty M. Effects of cell surface ganglioside sialidase inhibition on growth control and differentiation of human neuroblastoma cells.  Eur J Cell Biol . 1997;  73 1-9
    PubMedGoogle Scholar
  • 32 Di Cioccio A R, Srivastava B IS. Inhibition of deoxynucleotide-polymerizing enzyme activities of human cells and of simian sarcoma virus by heparin.  Cancer Res . 1978;  38 2401-2407
    PubMedGoogle Scholar
  • 33 Stetler-Stevenson W G, Hewitt R, Corcoran M. Matrix-metalloproteases and tumor invasion: from correlation and causality to the clinic.  Semin Cancer Biol . 1996;  7 147-154
    CrossrefPubMedGoogle Scholar
  • 34 Zacharski L R, Wojtukiewicz M Z, Constantini V, Ornstein D L, Memoli V A. Pathways of coagulation/fibrinolysis activation in malignancy.  Semin Thromb Haemost . 1992;  18 104-116
    PubMedGoogle Scholar
  • 35 Fenton J. Thrombin and cancer. In: Piffare R, ed. New Anticoagulants for the Cardiovascular Patient Philadelphia: Hanley and Belfus 1997: 517-520
    Google Scholar
  • 36 Schmitt M, Harbeck N, Thomssen C. Clinical aspects of plasminogen activation system in tumor invasion and metastasis: prognostic relevance and targets for therapy.  Thromb Haemost . 1997;  78 285-296
    PubMedGoogle Scholar
  • 37 van Meyer M, Smilde A, Tans G. The suicide substrate reaction between plasminogen activator inhibitor 1 and thrombin is regulated by the cofactors vitronectin and heparin.  Blood . 1997;  90 1874-1882
    PubMedGoogle Scholar
  • 38 Espana F, Estelles A, Fernandez P J. Evidence for the regulation of urokinase and tissue type plasminogen activators by serpin, protein C inhibitor, in semen and blood plasma.  Thromb Haemost . 1993;  70 989-994
    PubMedGoogle Scholar
  • 39 Tyagi S C, Kumar S, Katwa L. Differential regulation of extracellular matrix metalloproteinase and tissue inhibitor by heparin and cholesterol in fibroblast cells.  J Mol Cell Cardiol . 1997;  29 391-404
    CrossrefPubMedGoogle Scholar
  • 40 Marsh N A, Minter A J, Hesterman C N. The effect of heparin and other glycosaminoglycans on the levels of tissue plasminogen activator and plasminogen activator inhibitor in cultured human umbilical vein endothelial cells.  Blood Coagul Fibrinolysis . 1990;  1 133-138
    PubMedGoogle Scholar
  • 41 Nelson R M, Cecconi O, Roberts W G. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation.  Blood . 1993;  82 3253-3258
    PubMedGoogle Scholar
  • 42 Abbate R, Gori A M, Modesti P A. Heparin, monocytes, and procoagulant activity.  Haemostasis . 1990;  20(Suppl 1) 98-100
    PubMedGoogle Scholar
  • 43 Au Y PT, Kenagy R D, Clowes M M, Clowes A W. Mechanism of inhibition by heparin of vascular smooth muscle cell proliferation and migration.  Haemostasis . 1993;  23(Suppl 1) 177-182
    PubMedGoogle Scholar
  • 44 Cerletti C, Rajtar G, Marchi E, De Gaetano G. Interaction between glycosaminoglycans, platelets, and leukocytes.  Semin Thromb Hemost . 1994;  20 245-253
    PubMedGoogle Scholar
  • 45 Vlodavsky I, Mohsen M, Lider O. Inhibition of tumor metastasis by heparanase inhibiting species of heparin.  Invasion Metastasis . 1995;  14 290-302
    PubMedGoogle Scholar
  • 46 Parish C R, Coombe D R, Jakobsen K B, Bennett F A, Underwood P A. Evidence that sulphated polysaccharides inhibit tumor metastasis by blocking tumor-cell-derived heparanases.  Int J Cancer . 1987;  40 511-518
    PubMedGoogle Scholar
  • 47 Maeda S, Kimura H, Koga N, Lin K H, Saito T. Cell density-dependent DNA fragmentation and its suppression by heparin in primary culture of adult rat hepatocytes.  Biochem Biophys Res Commun . 1993;  195 270-275
    CrossrefPubMedGoogle Scholar
  • 48 Wang A, Templeton D M. Inhibition of mitogenesis and c-fos induction in mesangial cells by heparin and heparan sulfates.  Kidney Int . 1996;  49 437-438
    PubMedGoogle Scholar
  • 49 Bianconi L, Martino A D, Orlandi V. Development of inflammatory angiogenesis by local stimulation of Fas in vivo.  J Exp Med . 1997;  186 147-152
    CrossrefPubMedGoogle Scholar
  • 50 Manaster J, Chezar J, Shurtz-Swirski R. Heparin induces apoptosis in human peripheral blood neutrophils.  Br J Haematol . 1996;  94 48-52
    CrossrefPubMedGoogle Scholar
  • 51 Granerus M, Engstrom W. Growth factors and apoptosis.  Cell Prolif . 1996;  29 309-314
    PubMedGoogle Scholar
  • 52 Wright S C, Wei Q S, Zhong J. Purification of a 24-kD protease from apoptotic tumor cells that activates DNA fragmentation.  J Exp Med . 1994;  180 2113-2123
    CrossrefPubMedGoogle Scholar
  • 53 Maia R C, Wagner K, Cabral R H, Rumjanek V M. Heparin rhodamine 123 extrusion by multidrug resistant cells.  Cancer Lett . 1996;  106 101-108
    CrossrefPubMedGoogle Scholar
  • 54 Folkman J, Langer R, Linhardt R J, Haudenschild C, Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone.  Science . 1983;  221 719-725
    PubMedGoogle Scholar
  • 55 Jacobson A M, Hahnenberger R. Antiangiogenic effect of heparin and other sulphated glycosamino-glycans in the chick embryo chorioallantoic membrane.  Phamacol Toxicol . 1991;  69 122-126
    PubMedGoogle Scholar
  • 56 Derbyshire E J, Comin G A, Yang Y C. Anti-tumor and anti-angiogenic effects in mice of heparin conjugated to angiostatic steroids.  Int J Cancer . 1995;  63 694-701
    PubMedGoogle Scholar
  • 57 Ziche M, Ruggiero M, Pasquali F, Chiarugi V P. Effects of cortisone with and without heparin on angiogenesis induced by prostaglandin E1 and by S180 cells, and on growth of murine transplantable tumors.  Int J Cancer . 1985;  35549-35552
    PubMedGoogle Scholar
  • 58 }Thorpe P E, Derbyshire E J, Andrade S P. Heparin-steroid conjugates: new angiogenesis inhibitors with antitumor activity in mice.  Cancer Res . 1993;  53 3000-3007
    PubMedGoogle Scholar
  • 59 Quyyumi A A, Diodati J G, Lakatos E, Bonow R O, Epstein S E. Angiogenic effect of low molecular weight heparin in patients with stable coronary artery disease: a pilot study.  J Am Coll Cardiol . 1993;  22 635-641
    PubMedGoogle Scholar
  • 60 Norrby K, Ostergaard P. Basic-fibroblast-growth-factor-mediated de novo angiogenesis is more effectively suppressed by low-molecular-weight heparin than by high-molecular-weight heparin.  Int J Microcirc . 1996;  16 8-15
    PubMedGoogle Scholar
  • 61 Jayson G C, Gallagher J T. Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells.  Br J Cancer . 1997;  75 9-16
    PubMedGoogle Scholar
  • 62 Sciumbata T, Caretto P, Pirovano P. Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long term survival.  Invasion Metastasis . 1996;  16 132-143
    PubMedGoogle Scholar
  • 63 Duroux P. A randomised trial of subcutaneous low-molecular-weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis.  Thromb Haemost . 1991;  65 251-256
    PubMedGoogle Scholar
  • 64 Sakuragawa N, Hasegawa H, Maki M, Nakagawa M, Nakashima M. Clinical evaluation of low-molecular-weight heparin on disseminated intravascular coagulation (DIC)-a multicenter co-operative double-blind trial in comparison with heparin.  Thromb Res . 1993;  72 475-500
    CrossrefPubMedGoogle Scholar
  • 65 Bergqvist D, Burmark V S, Flordal P A. Low-molecular-weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients.  Br J Surg . 1995;  82 496-501
    CrossrefPubMedGoogle Scholar
  • 66 Monreal M, Alastrue A, Rull M. Upper extremity deep venous thrombosis in cancer patients with venous access devices-prophylaxis with a low molecular weight heparin (Fragmin).  Thromb Haemost . 1996;  75 251-3
    PubMedGoogle Scholar
  • 67 The ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double blind randomized multicentre trial with venographic assessment.  Br J Surg . 1997;  84 1099-1103
    CrossrefPubMedGoogle Scholar
  • 68 Elias E, Shulka S, Mink I. Heparin and chemotherapy in the management of inoperable lung cancer.  Cancer . 1975;  36 129-136
    PubMedGoogle Scholar
  • 69 Halkin H, Goldberg J, Modan M, Modan B. Reduction of mortality in general medicine patients by low dose heparin prophylaxis.  Ann Intern Med . 1982;  96 561-565
    PubMedGoogle Scholar
  • 70 Torngren S, Reiger A. The influence of heparin and curable resection on the survival of colon cancer.  Acta Chir Scand . 1983;  149 427-429
    PubMedGoogle Scholar
  • 71 Kohanna F H, Sweeney J, Hussey S, Zacharski L R, Salzman E W. Effect of peri-operative low-dose heparin administration on the course of colon cancer.  Surgery . 1983;  93 433-438
    PubMedGoogle Scholar
  • 72 Wereldsma J, Bruggink E, Meijer W, Roukema J, van Patten W. Adjuvant portal liver infusion in colorectal cancer, with 5-fluorouracil/heparin versus urokinase versus control.  Cancer . 1990;  65 425-432
    PubMedGoogle Scholar
  • 73 Fielding L P, Hittinger R, Grace R H, Fry J S. Randomized controlled trial of adjuvant chemotherapy by portal vein infusion after curative resection for colorectal adenocarcinoma.  Lancet . 1992;  340 502-506
    CrossrefPubMedGoogle Scholar
  • 74 Kingston R, Fielding L D, Palmer M. Peri-operative heparin a possible adjuvant to surgery in colo-rectal cancer?.  Int J Colorectal Dis . 1993;  8 111-115
    CrossrefPubMedGoogle Scholar
  • 75 Weitz J L. Low molecular weight heparins.  N Engl J Med . 1997;  337 688-698
    CrossrefPubMedGoogle Scholar
  • 76 Piazolo L, Harenberg J, Malsch R, Huttner F G, Heene D L. Comparison of the pharmacodynamic and pharmacokinetic profiles of two low-molecular-mass heparins in rats.  Semin Thromb Hemost . 1997;  23 109-117
    PubMedGoogle Scholar